Rare Disease, Type 1 Diabetes, and Heart Function: Breakthroughs for Three CIRM-Funded Studies

This past week, there has been a lot of mention of CIRM funded studies that really highlight the importance of the work we support and the different disease areas we make an impact on. This includes important research related to rare disease, Type 1 Diabetes (T1D), and heart function. Below is a summary of the … Continue reading Rare Disease, Type 1 Diabetes, and Heart Function: Breakthroughs for Three CIRM-Funded Studies

Moving a great idea targeting diabetes out of the lab and into a company

It’s always gratifying to see research you have helped support go from being an intriguing idea to something with promise to a product that is now the focus of a company. It’s all the more gratifying if the product in question might one day help millions of people battling diabetes. That’s the case with a … Continue reading Moving a great idea targeting diabetes out of the lab and into a company

Stem Cell Agency Board Approves New Clinical Trial for Type 1 Diabetes

Today the governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $11.08 Million to Dr. Peter Stock at the University of California San Francisco (UCSF) to conduct a clinical trial for treatment of Type 1 Diabetes (T1D). The award brings the total number of CIRM funded clinical trials to 54.  T1D is a … Continue reading Stem Cell Agency Board Approves New Clinical Trial for Type 1 Diabetes

Breakthrough for type 1 diabetes: scientist discovers how to grow insulin-producing cells

More often than not, people don’t really think about their blood sugar levels before sitting down to enjoy a delicious meal, partake in a tasty dessert, or go out for a bicycle ride. But for type 1 diabetes (T1D) patients, every minute and every action revolves around the readout from a glucose meter, a device … Continue reading Breakthrough for type 1 diabetes: scientist discovers how to grow insulin-producing cells

CIRM-supported Type I Diabetes treatment enters clinical trials in Europe

ViaCyte, a company that CIRM has supported for many years, has announced international expansion of a clinical trial to test their therapeutic PEC-Direct product in patients with Type I Diabetes. The first European patient in Brussels was implanted with the PEC-Direct product candidate that, in animal models, is able to form functional beta cells. Patients … Continue reading CIRM-supported Type I Diabetes treatment enters clinical trials in Europe

How CIRM support helped a promising approach to type 1 diabetes get vital financial backing

The “Valley of Death” sounds like a scary place from “Lord of the Rings” or “Game of Thrones” that our heroes have to navigate to reach safety. The reality is not that different. It’s the space that young companies have to navigate from having a good idea to getting financial backing, so they can move … Continue reading How CIRM support helped a promising approach to type 1 diabetes get vital financial backing

New partnership to make CIRM supported treatment for type 1 diabetes even better

  ViaCyte, a regenerative medicine company long backed by CIRM, announced a partnership with CRISPR Therapeutics to increase the number of people with Type 1 Diabetes (T1D) who could benefit from their PEC-Direct therapeutic implant. Last year, CIRM granted ViaCyte $20 million to facilitate development of PEC-Direct, a device that both transplants pancreatic progenitor stem … Continue reading New partnership to make CIRM supported treatment for type 1 diabetes even better

Stem Cell Roundup: Gene therapy for diabetes, alcohol is bad for your stem cells and hairy skin

The start of a new year is the perfect opportunity to turn a new leaf. I myself have embraced 2018 with open arms and decided to join my fellow millennials who live and die by the acronym YOLO. How am I doing this? Well, so far, I got a new haircut, I started doing squats … Continue reading Stem Cell Roundup: Gene therapy for diabetes, alcohol is bad for your stem cells and hairy skin

Stories that caught our eye: How dying cells could help save lives; could modified blood stem cells reverse diabetes?; and FDA has good news for patients, bad news for rogue clinics

Growing up I loved watching old cowboy movies. Invariably the hero, even though mortally wounded, would manage to save the day and rescue the heroine and/or the town. Now it seems some stem cells perform the same function, dying in order to save the lives of others. Researchers at Kings College in London were trying … Continue reading Stories that caught our eye: How dying cells could help save lives; could modified blood stem cells reverse diabetes?; and FDA has good news for patients, bad news for rogue clinics

Stem cell stories that caught our eye: skin grafts fight diabetes, reprogramming the immune system, and Asterias expands spinal cord injury trial sites

Here are the stem cell stories that caught our eye this week. Skin grafts fight diabetes and obesity. An interesting new gene therapy strategy for fighting type 1 diabetes and obesity surfaced this week. Scientists from the University of Chicago made genetically engineered skin grafts that secrete a peptide hormone called glucagon-liked peptide-1 (GLP-1). This … Continue reading Stem cell stories that caught our eye: skin grafts fight diabetes, reprogramming the immune system, and Asterias expands spinal cord injury trial sites